[ Contents | Search | Next | Previous | Up ]
From: Lisa LaSalle
Date: 21 Oct 2012
Time: 12:43:02 -0500
Remote Name: 96.251.126.134
Ora, Thanks for re-stating your question. I would argue that there *has* been interest in this area in recent years - see pp. 376-379 in Nan's & Oliver Bloodstein's co-authored Handbook on Stuttering (2008) and Yairi & Seery (2011), Guitar & McCauley (2010), etc. and new drug therapies that as Nan says only shows a reduction in severity from baseline, but still might be worth the risks for some individuals who stutter. Why are drug therapies not more popular among SLPs? Perhaps simply because we don't prescribe them - we would refer to those who do, if and only if there is a real interest in this option from an older client who stutters.